Fasting Before and After Chemotherapy for Ovarian Cancer: A Promising Strategy?
Recent research suggests that fasting before and after chemotherapy may offer significant benefits for patients with high-grade serous ovarian carcinoma (HGSOC), the most common and lethal form of ovarian cancer. A pilot randomized clinical trial conducted in Rome, Italy, found that short-term fasting during chemotherapy cycles reduced insulin levels and improved treatment outcomes, including stronger tumor responses and longer progression-free survival. These findings, reported by the American Society of Clinical Oncology (ASCO), highlight a potential new approach to enhance cancer care.
The Study: Key Findings and Methodology
The study, published in the ASCO Perspective, involved 36 patients with HGSOC. Participants were randomized to either fast for a short period before and after each chemotherapy cycle or follow a regular eating pattern. After three cycles of neoadjuvant chemotherapy, the fasting group showed a notable reduction in insulin levels compared to the control group. This metabolic shift was associated with improved pathologic responses and extended progression-free survival.
“Fasting during chemotherapy is an area of growing research interest,” said Eleonora Teplinsky, MD, a gynecologic oncologist at Valley-Mount Sinai Comprehensive Cancer Care. “While this is a small study, the findings are encouraging and suggest that fasting could be a promising complementary strategy for certain ovarian cancer patients.”
Why Insulin Matters in Cancer Treatment
Insulin, a hormone that regulates blood sugar, has been linked to cancer progression in several studies. Elevated insulin levels can promote tumor growth by activating signaling pathways that support cell proliferation, and survival. By reducing insulin, fasting may create an environment less favorable for cancer cells, potentially enhancing the effectiveness of chemotherapy.
The study’s results align with broader research on metabolic interventions in oncology. A 2022 narrative review published in *Cancer Science* noted that fasting could limit cancer cells’ adaptability by restricting their access to nutrients and energy sources, though larger trials are needed to confirm these effects in diverse patient populations.
Implications for Ovarian Cancer Care
Ovarian cancer is the deadliest gynecologic cancer in the United States, with HGSOC accounting for 70% to 80% of related deaths. Often diagnosed at advanced stages, HGSOC typically requires surgery combined with chemotherapy. The ASCO study adds to a growing body of evidence that lifestyle and metabolic factors may influence treatment outcomes.
However, experts caution that fasting should not replace standard care. “This is a pilot study, and more research is needed to determine the optimal fasting protocols, patient eligibility, and long-term safety,” emphasized Dr. Teplinsky. “Patients should always consult their oncologists before making significant dietary changes.”
Future Directions and Challenges
The next step is to validate these findings in larger, multicenter trials. Researchers are also exploring how fasting interacts with different chemotherapy regimens and whether it benefits other cancer types. While the mechanism is not fully understood, the potential to improve treatment responses without additional drugs is a compelling area of investigation.
For now, the ASCO study offers hope that simple, non-invasive strategies like fasting could complement traditional therapies. As Dr. Teplinsky noted, “These results underscore the importance of interdisciplinary research in oncology, where insights from metabolism and nutrition may open new pathways for patient care.”
Key Takeaways
- Fasting before and after chemotherapy may reduce insulin levels in HGSOC patients.
- Early results suggest improved tumor responses and longer progression-free survival.
- Larger trials are needed to confirm these findings and establish guidelines.
- Fasting should not replace standard cancer treatments but may be explored as an adjunct.